By acting on a different functional domain of Bcl-2 than BH3 mimetics, these tools could provide additional opportunities to kill these cancers, and to be used as follow-up strategies to kill venetoclax-resistant or -relapsed cancers, or to participate in combination therapies with venetoclax via their ability to boost endogenous Bim levels. Here, BCL2 is linked to cancer.